• Rheumatoid Arthritis
    • Josef Sebastian Smolen
    • Josef Sebastian Smolen: Influence Statistics

      Josef Sebastian Smolen

      Josef Sebastian Smolen

      Show email address

      Rheumatology, Medical University of Vienna, Wien, Austria | University of Vienna, Vienna, Austria. | Department of Internal Medicine III, Medical University of Vienna, Vienna, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Josef Sebastian Smolen:Expert Impact

      Concepts for whichJosef Sebastian Smolenhas direct influence:Rheumatoid arthritis,Psoriatic arthritis,Systemic lupus erythematosus,Patients rheumatoid arthritis,Lupus erythematosus,Arthritis rheumatoid,Radiographic progression,Systemic lupus.

      Josef Sebastian Smolen:KOL impact

      Concepts related to the work of other authors for whichfor which Josef Sebastian Smolen has influence:Rheumatoid arthritis,Systemic lupus erythematosus,Autoimmune diseases,Necrosis factor,Ankylosing spondylitis,Lupus nephritis,Sle patients.

      KOL Resume for Josef Sebastian Smolen


      Rheumatology, Medical University of Vienna, Wien, Austria


      Department of Rheumatology, Medical University of Vienna, Vienna, Austria


      Department of Medicine 3, Division of Rheumatology, Vienna, AUSTRIA

      Division of Rheumatology, Medical University of Vienna, Wien, Austria


      From the Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen; The Rheumatology Research Unit, Department of Rheumatology, Odense University Hospital; Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute; Children's Hospital of Eastern Ontario Research Institute; Department of Pediatrics and School of Rehabilitation Sciences, University of Ottawa, Ottawa; Institute for Work and Health, Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam Public Health; Department of Epidemiology and Biostatistics; Amsterdam Rheumatology and Immunology Center; Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam; Department of Rheumatology, and Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre; Care and Public Health Research Institute, Maastricht University, Maastricht; University of Twente, Department of Psychology, Health and Technology, Enschede, the Netherlands; Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles; Medicine Service, VA Medical Center, Birmingham; Department of Medicine, School of Medicine, University of Alabama, and Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, Alabama; Department of Rehabilitation and Movement Science, College of Nursing and Health Sciences, University of Vermont, Burlington, Vermont; University of Washington, Seattle, Washington, USA; Swiss Paraplegic Research, Nottwil, Switzerland; Université de Lorraine, EA 4360 Approches Épidémiologiques et Psychologiques (APEMAC), Nancy, France; University of Florence, Florence, Italy; Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria; European Medicines Agency, London, UK; Faculty of Medicine and Health University of Sydney and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia.

      Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, AUSTRIA

      Medical University of Vienna, Vienna, Austria. Electronic address:

      Department of Medicine 3, Medizinische Universitat Wien, Wien, Austria


      Medical Univ. of Vienna, Vienna, Austria

      ReFlaP study working group, PARIS, France

      Department of Immunology, University of Vienna


      Rheumatology, Medical University of Vienna, Vienna

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Josef Sebastian Smolen is among the top experts in the world.
      Concept World rank
      ra33 antibodies #1
      htnftg animals #1
      93 evaluation #1
      autoantibodies mortality #1
      structural damage jsn #1
      p38mapkalpha erk #1
      flare radiographic progression #1
      nuclear autoantigen ra33 #1
      established early #1
      tnfi efficacy #1
      wobenzym #1
      mmicount #1
      4 placebo #1
      great unknown #1
      baseline igg #1
      mmp3 levels week #1
      early mtx #1
      cdai das28 #1
      symptoms active #1
      modified disease #1
      ra33 autoantibodies #1
      rtxeu rtxus #1
      mtx optima #1
      addition acpa #1
      arthritis cdapsa #1
      vlda mda mda #1
      scf expression sfb #1
      reliability pain #1
      patients 10 socs #1
      eumuscnetproject #1
      icf core sle #1
      methotrexate week #1
      european league #1
      disease activity pain #1
      items obquest #1
      gp2013 rtxeu #1
      antibodies antinuclear autoimmune #1
      raynaud phenomenon patients #1
      aapa patients #1
      rheumatoid arthritis sdai #1
      mrna patients #1
      sdzrtx refrtx #1
      bone resorption repair #1
      gap≥30 #1
      esr crp esr #1
      occupational balance components #1
      rituximab psoriatic arthritis #1
      synthetic biological dmards #1
      mda psa dapsa #1
      rem 6 months #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Josef Sebastian Smolen

      KOL-Index: 28323

      BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative efficacy of tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequate response to methotrexate.

      METHODS: ORAL Strategy was a 1 year, double-blind, phase 3b/4, head-to-head, non-inferiority, ...

      Known for Tofacitinib Monotherapy | Rheumatoid Arthritis | Methotrexate Patients | Combination Therapy | Oral Strategy
      KOL-Index: 22837

      BACKGROUND: Upadacitinib, an oral Janus kinase (JAK)1-selective inhibitor, showed efficacy in combination with stable background conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with rheumatoid arthritis who had an inadequate response to DMARDs. We aimed to evaluate the safety and efficacy of upadacitinib monotherapy after switching from methotrexate versus continuing methotrexate in patients with inadequate response to methotrexate.

      METHODS: ...

      Known for Inadequate Response | Rheumatoid Arthritis | Upadacitinib 15 | Week Patients | 3 Study
      KOL-Index: 21356

      BACKGROUND: Clinical remission and low disease activity are essential treatment targets in patients with rheumatoid arthritis. Although moderately active rheumatoid arthritis is common, treatment effects in moderate disease have not been well studied. Additionally, optimum use of biologics needs further investigation, including the use of induction, maintenance, and withdrawal treatment strategies. The aim of the PRESERVE trial was to assess whether low disease activity would be ...

      Known for Methotrexate Patients | Low Disease Activity | Rheumatoid Arthritis | Randomised Controlled Trial | Treatment Etanercept
      KOL-Index: 21052

      BACKGROUND: Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone are unclear. The OPTIMA trial assessed different treatment adjustment strategies in patients with early rheumatoid arthritis attaining (or not) stable low disease activity with adalimumab plus methotrexate or methotrexate monotherapy.

      METHODS: This trial was done at 161 sites worldwide. ...

      Known for Methotrexate Patients | Low Disease | Rheumatoid Arthritis | Primary Endpoint | Activity Adalimumab
      KOL-Index: 20364

      OBJECTIVE: To investigate the efficacy of single and combined blockade of tumor necrosis factor (TNF), interleukin-1 (IL-1), and RANKL pathways on synovial inflammation, bone erosion, and cartilage destruction in a TNF-driven arthritis model.

      METHODS: Human TNF-transgenic (hTNFtg) mice were treated with anti-TNF (infliximab), IL-1 receptor antagonist (IL-1Ra; anakinra), or osteoprotegerin (OPG; an OPG-Fc fusion protein), either alone or in combinations of 2 agents or all 3 agents. ...

      Known for Bone Erosion | Cartilage Destruction | Tumor Necrosis Factor | Synovial Inflammation | Induced Arthritis
      KOL-Index: 19621

      Local bone erosion and systemic bone loss are hallmarks of rheumatoid arthritis and cause progressive disability. Tumor necrosis factor (TNF) is a key mediator of arthritis and acts catabolically on bone by stimulating bone resorption and inhibiting bone formation. We hypothesized that the concerted action of anti-TNF, which reduces inflammation and parathyroid hormone (PTH), which stimulates bone formation, or osteoprotegerin (OPG), which blocks bone resorption and could lead to repair ...

      Known for Bone Erosions | Parathyroid Hormone | Necrosis Factor | Pth Opg | Anti Tnf
      KOL-Index: 19564

      BACKGROUND: Tumour necrosis factor alpha (TNFalpha) inhibitors are frequently used to treat rheumatoid arthritis, but whether use of a different TNFalpha inhibitor can improve patient response is unknown. We assess the efficacy and safety of the TNFalpha inhibitor golimumab in patients with active rheumatoid arthritis who had previously received one or more TNFalpha inhibitors.

      METHODS: 461 patients with active rheumatoid arthritis from 82 sites in 10 countries were randomly allocated by ...

      Known for Rheumatoid Arthritis | Patients Placebo | 50 Golimumab | Monoclonal Antibodies | Necrosis Factor
      KOL-Index: 18929

      BACKGROUND: Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate, a standard treatment for this disease. There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacious in relief of signs and symptoms. We therefore investigated whether infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody would provide additional clinical benefit to patients who had active rheumatoid arthritis despite receiving methotrexate.

      METHODS: In an ...

      Known for Methotrexate Patients | Rheumatoid Arthritis | 30 Weeks | Α Monoclonal Antibody | Necrosis Factor
      KOL-Index: 18805

      OBJECTIVE: To evaluate the efficacy and safety of repeated administration of infliximab plus methotrexate (MTX) over a 2-year period in patients with rheumatoid arthritis (RA) who previously experienced an incomplete response to MTX.

      METHODS: Four hundred twenty-eight patients were randomly assigned to receive MTX plus placebo or infliximab at a dose of 3 or 10 mg/kg plus MTX for 54 weeks, with an additional year of followup. The protocol was later amended to allow for continued ...

      Known for Physical Function | Infliximab Mtx | Structural Damage | Rheumatoid Arthritis | Sustained Improvement
      KOL-Index: 18699

      OBJECTIVES: To compare the efficacy, safety, immunogenicity and pharmacokinetics (PK) of SB2 to the infliximab reference product (INF) in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate therapy.

      METHODS: This is a phase III, randomised, double-blind, multinational, multicentre parallel group study. Patients with moderate to severe RA despite methotrexate therapy were randomised in a 1:1 ratio to receive either SB2 or INF of 3 mg/kg. The primary end point ...

      Known for Sb2 Inf | Methotrexate Therapy | Rheumatoid Arthritis | Efficacy Safety | Reference Product
      KOL-Index: 18698

      BACKGROUND: To date, head-to-head trials comparing the efficacy and safety of biological disease-modifying antirheumatic drugs within the same class, including TNF inhibitors, in patients with active rheumatoid arthritis despite methotrexate therapy are lacking. We aimed to compare the efficacy and safety of two different TNF inhibitors and to assess the efficacy and safety of switching to the other TNF inhibitor without a washout period after insufficient primary response to the first ...

      Known for Certolizumab Pegol | Tnf Inhibitor | Efficacy Safety | Adalimumab Rheumatoid Arthritis | Week Patients
      KOL-Index: 18299

      OBJECTIVE: To validate and compare the definition of the Disease Activity Score 28 based on C-reactive protein (DAS28 (CRP)) to the definition based on erythrocyte sedimentation rate (ESR).

      METHODS: Data were analysed from two randomised, double-blind, placebo-controlled trials of abatacept of 6-month and 12-month duration in patients with rheumatoid arthritis. European League Against Rheumatism (EULAR) response criteria and the proportion of patients in remission (DAS28 <2.6) based on ...

      Known for European League | Rheumatoid Arthritis | Erythrocyte Sedimentation Rate | Response Criteria | Das28 Based
      KOL-Index: 17770

      OBJECTIVE: To assess the relationship between inflammation and joint destruction in rheumatoid arthritis (RA) patients who have not responded clinically to treatment.

      METHODS: Changes from baseline to week 54 in clinical variables and measures of radiographic progression were compared between patients who received infliximab (3 mg/kg or 10 mg/kg every 4 or 8 weeks) plus methotrexate (MTX) and those who received MTX plus placebo in the Anti-Tumor Necrosis Factor Trial in RA with ...

      Known for Infliximab Mtx | Clinical Improvement | Rheumatoid Arthritis Patients | Necrosis Factor | Radiographic Benefit
      KOL-Index: 17615

      OBJECTIVE: To identify disease characteristics leading to progression of joint damage in patients with early rheumatoid arthritis (RA) treated with methotrexate (MTX) versus those treated with infliximab plus MTX.

      METHODS: Patients who had not previously been treated with MTX with active RA were randomly assigned to receive escalating doses of MTX up to 20 mg/week plus placebo or infliximab at weeks 0, 2, and 6, and every 8 weeks thereafter through week 46. Radiographic joint damage was ...

      Known for Joint Damage | Mtx Infliximab | Early Rheumatoid Arthritis | Radiographic Progression Patients | Baseline Week
      KOL-Index: 17425

      BACKGROUND: Interleukin 6 is involved in the pathogenesis of rheumatoid arthritis via its broad effects on immune and inflammatory responses. Our aim was to assess the therapeutic effects of blocking interleukin 6 by inhibition of the interleukin-6 receptor with tocilizumab in patients with rheumatoid arthritis.

      METHODS: In this double-blind, randomised, placebo-controlled, parallel group phase III study, 623 patients with moderate to severe active rheumatoid arthritis were randomly ...

      Known for Rheumatoid Arthritis | Tocilizumab Placebo | Receptor Inhibition | Patients 8 | Monoclonal Antibodies

      Key People For Rheumatoid Arthritis

      Top KOLs in the world
      Paul Emery
      rheumatoid arthritis ankylosing spondylitis radiographic progression
      Josef Sebastian Smolen
      rheumatoid arthritis systemic lupus erythematosus radiographic progression
      James F Fries
      rheumatoid arthritis physical function systemic lupus erythematosus
      John Turner Sharp
      rheumatoid arthritis radiographic progression joint space width
      Frederick J Wolfe
      rheumatoid arthritis work disability rheumatic diseases
      Matthew H Liang
      rheumatoid arthritis systemic lupus erythematosus lyme disease

      Rheumatology, Medical University of Vienna, Wien, Austria | University of Vienna, Vienna, Austria. | Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria | Division of Rheumatology, Department of Medicine 3, Medical Univ

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.